Table 4.
Adjusted models for the primary cardiometabolic outcomes between KS and controls
| Outcome | Obesity | Testosterone Rx | Antipsychotic Rx | All covariatesa |
|---|---|---|---|---|
| Overweight/obesity | — | 1.52 (1.30-1.79)b | 1.50 (1.31-1.73)b | 1.49 (1.27-1.75)b |
| Dyslipidemia | 2.50 (1.85-3.37)b | 1.81 (1.22-2.67)b | 2.58 (1.93-3.44)b | 1.60 (1.07-2.40) |
| Dysglycemia | — | 1.81 (1.05-3.13) | 1.56 (0.98-2.48) | 1.84 (1.07-3.16) |
| Hypertension | 0.80 (0.61-1.06) | 1.02 (0.73-1.41) | 0.85 (0.64-1.12) | 0.84 (0.59-1.18) |
| Liver dysfunction | 1.78 (1.42-2.23)b | 1.98 (1.52-2.58)b | 1.77 (1.40-2.24) | 1.71 (1.30-2.25)b |
The models control for the addition of obesity, testosterone treatment, antipsychotic treatment, and the combined effect of all of those risk factors on cardiometabolic health. All of these models include the covariate age at most recent visit. Data are shown as OR and 95% CI.
Abbreviation: Rx, prescription.
a The outcomes of overweight/obesity and dysglycemia did not include overweight/obese in the model.
b Statistically significant at an alpha of 0.01.